Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple Dose Study of ABBV-8E12 in Progressive Supranuclear Palsy
2016-001635-12Phase 2Terminated
- Sponsor
- AbbVie Inc.
- Start
- Feb 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in progressive supranuclear palsy (PSP) comparing ABBV-8E12 with Placebo (2 arms). Primary endpoint: Change from baseline to Week 52 on PSP Rating Scale total score. Started Feb 2017; status: terminated.
02
Drugs
tilavonemab
03
Conditions
progressive supranuclear palsy (PSP)
Beyond the preview
Go deeper on 2016-001635-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001635-12.